Poland Study Finds Cannabinoid Ointment Relieves Eczema Symptoms
Eczema is a common skin condition that causes dry, itchy, and inflamed skin in people who suffer from it. Eczema is also known as atopic dermatitis. Researchers estimate that roughly 10% to 20% of children and 2% to 10% of adults worldwide have eczema.
Common treatments for eczema include over-the-counter products that may help to some degree. Pharmaceutical drugs are also sometimes prescribed for eczema sufferers, including non-steroid topical creams, steroid topical creams, and daily pill prescriptions.
A team of researchers in Poland recently conducted a study examining the application of cannabinoid-based ointments and eczema. Below is more information about the study and its findings via a news release from NORML:
Katowice, Poland: The topical administration of an ointment containing standardized percentages of CBD and CBG (cannabigerol) mitigates symptoms and improves the health-related quality of life in patients with atopic dermatitis (eczema), according to observational data published in the journal Clinical, Cosmetic and Investigational Dermatology.
Polish investigators assessed the transdermal use of cannabinoids in nine patients diagnosed with AD. Study participants applied a cannabinoid-infused ointment containing 30 percent CBD and five percent CBG daily for eight weeks.
Cannabis treatment led to the remission of skin lesions and other changes in skin parameters, including improved hydration and less itching.
“Our results demonstrate that topical cannabinoid therapy is effective in reducing itching and improving the quality of life of patients with AD, leading to symptom remission in some cases,” the study’s authors concluded.
The results are consistent with those of prior studies finding that the topical application of cannabinoids provides benefits in treating various skin-related conditions, including psoriasis, erythema, pruritus, and acne. Cannabinoid treatment is also associated with wound healing in patients with refractory leg ulcers and has demonstrated positive results in patients suffering from the skin blistering disease epidermolysis bullosa.
Full text of the study, “Evaluation of biophysical parameters of the skin of patients with atopic dermatitis after application of an ointment containing 30% cannabidiol and 5% cannabigerol,” appears in Clinical, Cosmetic and Investigational Dermatology.
